Source: https://www.siboncoj.ru/jour/article/view/910
Timestamp: 2019-04-25 00:26:11+00:00

Document:
1. De Pace N. Sulla scomparsa di un enorme cancro vegetante del collo dell’utero senza cura chirurgica. Ginecologia. 1912; 9: 82-89.
2. Ottolino-Perry K., Diallo J.S., Lichty B.D., Bell J.C., McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010; 18 (2): 251-263. doi: 10.1038/mt.2009.283.
3. Fournier P., Schirrmacher V. Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology (Basel). 2013 Jul 2; 2 (3): 936-75. doi: 10.3390/biology2030936.
4. Alexander D.J. Historical aspects. Newcastle disease. Boston: Kluwer Academic Publishers. 1988: 1-10.
5. Dimitrov K.M., Ramey AM., Qiu X., Bahl J., Afonso C.L. Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus). Infect Genet Evol. 2016 Apr; 39: 22-34. doi: 10.1016/j.meegid.2016.01.008.
6. Dimitrov K.M., Afonso C.L., Yu Q., Miller PJ. Newcastle disease vaccines A solved problem or a continuous challenge? Vet Microbiol. 2017 Jul; 206: 126-136. doi: 10.1016/j.vetmic.2016.12.019.
7. Schirrmacher V. Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients. Int J Mol Sci. 2017 May 20; 18 (5). pii: E1103. doi: 10.3390/ijms18051103.
8. Cassel W.A., Garrett R.E. Newcastle disease virus as an antineoplastic agent. Cancer. 1965; 18: 863-868.
9. Sinkovics J.G., Horvath J.C. Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol. 2000; 16: 1-15.
10. Csatary L.K. Viruses in the treatment of cancer. Lancet. 1971; 2 (7728): 825.
11. Miller P.J., Koch G. Newcastle disease. Diseases of Poultry. 13th ed. NJ, USA: Wiley-Blackwell; Hoboken. 2013. 89-138.
12. Юрченко К.С., Губанова Н.В., Шестопалова Л.В., Щелка-новМ.Ю., ШестопаловА.М. Онколитические свойства вируса болезни Ньюкасла. Тихоокеанский медицинский журнал. 2015; 3: 14—18.
13. Шестопалова Л.В., Максимова ДА., Красильникова АА., Корчагина К.В., Силко Н.Ю., Шестопалов А.М. Вирусы болезни Ньюкасла как перспективный агент для создания онколитических препаратов. Вестник НГУ. Серия: Биология, клиническая медицина. 2012; 10 (2): 232-242.
14. Tayeb S., Zakay-Rones Z., Panet A. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virother. 2015 Mar 27; 4: 49-62. doi: 10.2147/OV.S78600.
15. Zhang S., Sun Y., Chen H., Dai Y., Zhan Y., Yu S., Qiu X., Tan L., Song C., Ding C. Activation of the PKR/eIF2a signaling cascade inhibits replication of Newcastle disease virus. Virol J. 2014 Mar 31; 11: 62. doi: 10.1186/1743-422X-11-62.
16. Каверин Н.В., Львов Д.К., Щелканов М.Ю. Парамиксовирусы (Paramyxoviridae). Руководство по вирусологии. М., 2013. 192-197.
17. Sanchez-FelipeL., VillarE., Munoz-Barroso I. a2-3- and a2-6- N-linked sialic acids allow efficient interaction of Newcastle Disease Virus with target cells. Glycoconj J. 2012 Oct; 29 (7): 539-49. doi: 10.1007/s10719-012-9431-0.
18. Schirrmacher V. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines. 2016 Jul 20; 4 (3). pii: E16. doi: 10.3390/biomedicines4030016.
19. Porotto M., Salah Z., DeVito I., Talekar A., Palmer S.G., Xu R., Wilson I.A., Moscona A. The second receptor binding site of the globular head of the Newcastle disease virus (NDV) hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion. J Virol. 2012 May; 86 (10): 5730^1. doi: 10.1128/JVI.06793-11.
20. Molouki A., Peeters B. Rescue of recombinant Newcastle disease virus: Current cloning strategies and RNA polymerase provision systems. Arch Virol. 2017 Jan; 162 (1): 1-12. doi: 10.1007/s00705-016-3065-7.
21. Lundstrom K. New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy. Biologics. 2018 Feb 9; 12: 43-60. doi: 10.2147/BTT.S140114.
22. Kroemer G., Galuzzi I., Kepp O., Zitvogel I. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013; 31: 51-72. doi: 10.1146/annurev-immunol-032712-100008.
23. KomminothP., Roth J., Saremaslani P, Matias-Guiu X., Wolfe H. J., Heitz P. U. Polysialic acid of the neural cell adhesion molecule in the human thyroid: a marker for medullary thyroid carcinoma and primary C-cell hyperplasia. An immunohistochemical study on 79 thyroid lesions. Am J Surg Pathol. 1994 Apr; 18 (4): 399-411.
24. Lu D.Y., Lu T.R., Wu H.Y. Development of Antimetastatic Drugs by Targeting Tumor Sialic Acids. Sci Pharm. 2012 Jul-Sep; 80 (3): 497-508. doi: 10.3797/scipharm.1205-01.
25. Матвеева О.В., Кочиева Г.В., Нетесов С.В., Оникиенко С.Б., Чумаков П.М. Механизмы онколитического действия парамиксовируса сендай. Acta Naturae. 2015; 7 (2(25)): 6-16.
26. CohenM., Elkabets M., PerlmutterM., Porgador A., Voronov E., ApteR.N., LichtensteinR.G. Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immu-noediting. J Immunol. 2010 Nov 15; 185 (10): 5869-78. doi: 10.4049/jimmunol.1001635.
27. Santry L.A., McAusland T.M., Susta L., Wood G.A., Major Petrik J.J., Bridle B.W., Wootton S.K. Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer. Mol Ther Methods Clin Dev. 2017 Oct 16; 9: 181-191. doi: 10.1016/j.omtm.2017.10.004.
28. Elankumaran S., Rockemann D., Samal S.K. Newcastle Disease Virus Exerts Oncolysis by both Intrinsic and Extrinsic Caspase-Dependent Pathways of Cell Death. J Virol. 2006 Aug; 80: 7522-7534. doi: 10.1128/JVI.00241-06.
29. Kumar R., Tiwari A.K., Chaturvedi U., Kumar G.R., SahooA.P., Rajmani R.S., Saxena L., Saxena S., Tiwari S., Kumar S. Velogenic Newcastle disease virus as an oncolytic virotherapeutics: In vitro characterization. Appl Biochem Biotechnol. 2012 Aug; 167 (7): 2005-22. doi: 10.1007/s12010-012-9700-1.
30. Elmore S. Apoptosis:A Review of Programmed Cell Death. Toxicologic pathology. 2007; 35 (4): 495-516. doi:10.1080/01926230701320337.
31. ZamarinD., Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 2012 Mar; 7 (3): 347-67. doi: 10.2217/fmb.12.4.
32. Ch’ng W.C., StanbridgeE.J., Yusoff K., Shafee N. The Oncolytic Activity of Newcastle Disease Virus in Clear Cell Renal Carcinoma Cells in Normoxic and Hypoxic Conditions: The Interplay Between von Hippel-Lindau and Interferon-p Signaling. J Interferon Cytokine Res. 2013 Jul; 33 (7): 346-54. doi: 10.1089/jir.2012.0095.
33. Abdullah J.M., Mustafa Z., IderisA. Newcastle Disease Virus Interaction in Targeted Therapy against Proliferation and Invasion Pathways of Glioblastoma Multiforme. Biomed Res Int. 2014; 2014: 386470. doi: 10.1155/2014/386470.
34. Schirrmacher V., Fournier P. Harnessing oncolytic virus-mediated antitumor immunity. Front Oncol. 2014 Nov 24; 4: 337. doi: 10.3389/fonc.2014.00337.
35. Schirrmacher V. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Expert Opin Biol Ther. 2015; 15 (12): 1757-71. doi: 10.1517/14712598.2015.1088000.
36. Guo Z.S., Liu Z., Bartlett D.L. Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014 Apr 10; 4: 74. doi: 10.3389/fonc.2014.00074.
37. Schirrmacher V., Haas C., Bonifer R., Ertel C. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res. 1997 Jul; 3 (7): 1135-1148.
38. Schirrmacher V., Haas C., Bonifer R., Ahlert T., Gerhards R., Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 1999 Jan; 6: 63-73. doi: 10.1038/sj.gt.3300787.
39. Washburn B., Schirrmacher V. Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int. J. Oncol. 2002 Jul; 21: 85-93.
40. JarahianM., Watzl C., FournierP., A , DjandjiD., Zahedi S., Cerwenka A., Paschen A., Schirrmacher V., Momburg F. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol. 2009 Aug; 83: 8108-21. doi: 10.1128/JVI.00211-09.
41. Fujita M., Scheurer M.E., Decker S.A., McDonald HA., Kohan-bash G., Kastenhuber E.R., Kato H., Bondy M.L., Ohlfest J.R., Okada H. Role of type 1 IFNs in antiglioma immunosurveillance - Using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res. 2010 Jul 1; 16 (13): 3409-19. doi: 10.1158/1078-0432.CCR-10-0644.
42. Termeer C.C., Schirrmacher V, Brocker E.B., Becker J.C. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther. 2000 Feb; 7: 316-323. doi: 10.1038/sj.cgt.7700109.
43. Koks C.A., Garg A.D., Ehrhardt M., Riva M., Vandenberk L., Boon L., de Vleeschouwer S., Agostinis P, Graf N., van Gool S.W. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in ortheotopic glioma through the induction of immunogenic cell death. Int J Cancer. 2015 Mar 1; 136 (5): E313-25. doi: 10.1002/ijc.29202.
44. Schirrmacher V, Bai L., Umansky V, Yu L., Xing Y., Qian Z. Newcastle disease virus activates macrophages for anti-tumor activity. Int J Oncol. 2000 Feb; 16 (2): 363-373.
45. Zamarin D., Holmgaard R.B., Subudhi S.K., Park J.S., Man-sour M., Palese P, Merghoub T, Wolchok J.D., Allison J.P. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014 Mar 5; 6 (226): 226ra32. doi: 10.1126/scitranslmed.3008095.
46. Steiner H.H., Bonsanto MM., Beckhove P, Brysch M., Gelet-neky K., Ahmadi R., Schuele-Freyer R., Kremer P, Ranaie G., Matejic D., Bauer H., Kiessling M., Kunze S., Schirrmacher V, Herold-Mende C. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol. 2004; 22: 4272-4281. doi: 10.1200/JCO.2004.09.038.
47. Herold-Mende C., Karcher J., Dyckhoff G., Schirrmacher V. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. Adv Otorhinolaryn-gol. 2005; 62: 173-183. doi: 10.1159/000082507.
48. Cassel W.A., Murray D.R. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother. 1992; 9: 169-171.
49. Niu Z., Bai F., Sun T., Tian H., Yu D., Yin J., Li S., Li T., Cao H., Yu Q., Wu Y., Ren G., Li D. Recombinant Newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma model. Technol Cancer Res Treat. 2015 Oct; 14 (5): 607-15. doi: 10.7785/tcrt.2012.500414.
50. Pecora A.L., Rizvi N., Cohen G.I., Meropol N.J., Sterman D., Marshall J.L., Goldberg S., Gross P., O’Neil J.D., Groene W.S., Roberts M.S., Rabin H., Bamat M.K., Lorence RM. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002; 20: 2251-2266. doi: 10.1200/JCO.2002.08.042.
51. Wu Y., He J., An Y., Wang X., Liu Y, Yan S., Ye X., Qi J., Zhu S., Yu Q., Yin J., Li D., Wang W. Recombinant Newcastle disease virus (NDV/ ANH-IL-2) expressing human IL-2 as a potential candidate suppresses growth of hepatoma therapy. J Pharmacol Sci. 2016 Sep; 132 (1): 24-30. doi: 10.1016/j.jphs.2016.03.012.
52. Wu Y., He J., Geng J., An Y., YeX., Yan S., Yu Q., Yin J., Zhang Z., Li D. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. Eur J Pharmacol. 2017 May 5; 802: 85-92. doi: 10.1016/j.ejphar.2017.02.042.
53. Fournier P, Arnold A., Wilden H., Schirrmacher V. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol. 2012 Mar; 40 (3): 840-50. doi: 10.3892/ijo.2011.1265.
54. Roy D.G., Bell J.C. Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother. 2013 Oct 9; 2: 47-56. doi: 10.2147/OV.S36623.
55. Ricca JM., Oseledchyk A., Walther T., Liu C., MangarinL., Merghoub T., Wolchok J.D., Zamarin D. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Mol Ther. 2018 Apr 4; 26(4): 10081019. doi: 10.1016/j.ymthe.2018.01.019.
56. Kim Y., Clements D.R., Sterea AM., Jang H. W., Gujar ShA., LeeP. WK. Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy. Viruses. 2015 Dec 9; 7 (12): 6506-25. doi: 10.3390/v7122953.
57. Jennings V, Ilett E., Scott K., West E.J., Vile R., Pandha H., Harrington K., Young A., Hall G.D., Coffey M., Selby P., Errington-Mais F, Melcher A.A. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int J Cancer. 2014; 134 (5): 1091-101. doi:10.1002/ijc.28450.
58. Iankov I.D., Msaouel P., Allen C., Federspiel MJ., Bulur P.A., Dietz A.B., Gastineau D., Ikeda Y., Ingle J.N., Russell S.J., Galanis E. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat. 2010 Aug; 122 (3): 745-54. doi: 10.1007/s10549-009-0602-z.
59. Ilett E.J., Prestwich R.J., Kottke T., Errington F., Thompson JM., HarringtonK.J.,PandhaH.S., CoffeyM., SelbyPJ., VileRG.,MelcherAA. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 2009 May; 16 (5): 689-99. doi: 10.1038/gt.2009.29.
60. БалдуеваИА., НовикА.В., МоисеенкоВ.М., Нехаева Т.Л., Данилова А.Б., ДаниловА.О., Проценко С.А., Петрова Т.Ю., УлейскаяГ.И., Щёкина Л.А., Семёнова А.И., Михайличенко Т.Д., Телетаева ГМ., ЖабинаА.С., Волков Н.В., Комаров Ю.И. Клиническое исследование (II фаза) вакцины на основе аутологичных дендритных клеток с иммунологическим адъювантом у больных с меланомой кожи. Вопросы онкологии. 2012; 58 (2): 212-221.
61. Леплина О.Ю., Насонова Г.В., ТихоноваМ.А., Крючкова И.В., Лисуков И.А., Останин А.А., Черных Е.Р. IFNa-индуцированные дендритные клетки у больных множественной миеломой. Сибирский онкологический журнал. 2009; 6: 37-43.
62. Семилетова Ю.В., Анисимов В.В., Вагнер Р.И. Лечение больных первичной меланомой кожи. Современное состояние проблемы. Сибирский онкологический журнал. 2010; 4: 71-77.
63. Нехаева Т.Л. Оптимизация аутологичных дендритно-клеточных вакцин для лечения больных злокачественными новообразованиями. Сибирский онкологический журнал. 2013; 3: 52-56.
64. IlettE.J., PrestwichR.J., Kottke T., ErringtonF, Thompson J.M., HarringtonK.J., PandhaH.S., Coffey M, SelbyP.J., VileR.G.,Melcher A.A. Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report. Gene Ther. 2009 May; 16 (5): 689-99. doi: 10.1038/gt.2009.29.
65. Ahlert T., Sauerbrei W., Bastert G., RuhlandS., BartikB., Simian-tonaki N., Schumacher J., Hacker B., Schumacher M., Schirrmacher VJ. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccine in patients with breast or ovarian cancer. Clin. Oncol. 1997; 15: 1354-1366.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.